Trial Profile
Clinical Trial to Evaluate the Pharmacokinetics, Safety, and Tolerance of Single Dose Administration of a New Injectable Prolonged Release Formulation of Risperidone Using ISM Technology in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Autistic disorder; Bipolar disorders; Dementia; Schizophrenia
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Sponsors Rovi
- 15 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 26 Mar 2011 New trial record